Abstract
High-dose megestrol acetate, a synthetic progestin, has been advocated recently in treating patients with metastatic breast carcinoma; no significant increase in adverse effects has been reported. This report describes a patient with jaundice and intrahepatic cholestasis after high-dose megestrol acetate therapy. This cholestatic lesion may have a pathogenesis similar to that observed with estrogens and oral contraceptives.
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols*
-
Bilirubin / blood
-
Breast Neoplasms / drug therapy*
-
Cholestasis, Intrahepatic / chemically induced*
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Jaundice / chemically induced*
-
Mastectomy, Radical
-
Megestrol / administration & dosage
-
Megestrol / adverse effects
-
Megestrol / analogs & derivatives*
-
Megestrol Acetate
-
Methotrexate / administration & dosage
-
Prednisone / administration & dosage
-
Vincristine / administration & dosage
Substances
-
Vincristine
-
Cyclophosphamide
-
Megestrol
-
Bilirubin
-
Megestrol Acetate
-
Fluorouracil
-
Prednisone
-
Methotrexate